A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
08/1999
08/25/1999	EP0937150A2 Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors
08/25/1999	EP0937144A1 Human eosinophil-derived basic protein
08/25/1999	EP0937143A2 Secreted proteins and polynucleotides encoding them
08/25/1999	EP0937141A1 Polynucleotides encoding secreted proteins from human dendritic cells
08/25/1999	EP0937103A2 Compounds and methods for modulating cell adhesion
08/25/1999	EP0937101A1 Conformationally constrained lh-rh analogues, their uses and pharmaceutical compositions containing them
08/25/1999	EP0937095A1 Targeted cytolysis of cancer cells
08/25/1999	EP0937089A1 New knoevenagel condensation products, method for their production and their use
08/25/1999	EP0937070A1 Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
08/25/1999	EP0937045A1 N-aryl substituted tetrahydroquinolines ligands for retinoid receptors having agonist, antagonist or inverse agonist type activity
08/25/1999	EP0937042A1 Heteroaryl succinamides and their use as metalloproteinase inhibitors
08/25/1999	EP0937038A1 Vitamin d analogues
08/25/1999	EP0937036A1 Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors
08/25/1999	EP0936914A1 Hydroxy-phosphinyl derivatives useful as naaladase inhibitors
08/25/1999	EP0936913A1 Oral pharmaceutical preparation containing ibandronat
08/25/1999	EP0936912A1 Inhibitors of cysteine protease
08/25/1999	EP0237545B2 Production of pluripotent granulocyte colony-stimulating factor
08/25/1999	CN1226897A Isolated peptides derived from mage-2
08/25/1999	CN1226826A Method of treating malignant tumours with thyroxine analogues having no significant hormonal activity
08/25/1999	CN1226825A Use of amines to produce drugs for preventing tumour cell proliferation
08/25/1999	CN1226438A Composite mannosans peptides oral liquor
08/24/1999	US5942605 Antitumor agents synthesized from anthracycline 13-tosylhydrazone; side effect reduction
08/24/1999	US5942514 Tyrosine kinase inhibitors
08/24/1999	US5942489 Polypeptides with prolonged antagonistic duration; for treatment of diabetic retinopathy and nephropathy, and acromegaly; anticarcinogenic agents where cancer has somatomedin receptors
08/24/1999	US5942434 Regulatory sequence from phophoglycerate kinase operably linked to coding sequence of exogenous gene; for gene therapy; in situ expression of enzymes which convert prodrugs to active anticarcinogenic/antitumor drugs or cytokines
08/24/1999	US5942416 Treatment of infections from bacteria using polypeptides and polynucleotides
08/24/1999	US5942404 Diagnosing leukemia by incubating cells with specific antibodies and detecting surface antigens
08/24/1999	US5942235 Exogenous dna encoding an antigenic determinant of a pathogen; recombinant viruses and gene products are useful for cancer therapy
08/24/1999	US5942230 Composition of immunotoxins and retinoids and use thereof
08/24/1999	US5942209 Polymerizing a biodegradable, biocompatible polymer vehicle, e.g. epoxide-containing polymer, polyester, polyurethane, polyamide, polysulfone or an addition polymer, containing radionuclides; drug delivery
08/24/1999	CA2248972A1 Novel compounds
08/24/1999	CA2176974C Phenyl heterocycles as cyclooxygenase-2 inhibitors
08/24/1999	CA2075895C Compositions containing green porphyrins to destroy malignant cells in mononuclear cell populations
08/24/1999	CA2015197C Phenolic amine depigmenting and antimelanoma agents
08/20/1999	CA2249653A1 Novel compounds
08/19/1999	WO1999041402A2 Targeting of genetic vaccine vectors
08/19/1999	WO1999041387A2 Prostate-associated serine protease
08/19/1999	WO1999041376A2 Retinoblastoma protein complexes and retinoblastoma interacting proteins
08/19/1999	WO1999041375A2 Human receptor proteins
08/19/1999	WO1999041374A2 Human short-chain tnf-receptor family protein
08/19/1999	WO1999041373A2 Human transport-associated molecules
08/19/1999	WO1999041369A2 Genetic vaccine vector engineering
08/19/1999	WO1999041368A2 Optimization of immunomodulatory properties of genetic vaccines
08/19/1999	WO1999041359A1 Modified adenovirus containing a fiber replacement protein
08/19/1999	WO1999041283A1 Pf4 fragments and pharmaceutical compositions containing same
08/19/1999	WO1999041282A1 Therapeutic uses of keratinocyte growth factor-2
08/19/1999	WO1999041269A1 Oligodeoxyribonucleotides comprising o6-benzylguanine and their use
08/19/1999	WO1999041264A1 Methods of synthesizing gm3
08/19/1999	WO1999041252A1 Antagonists of gonadotropin releasing hormone
08/19/1999	WO1999041251A1 Antagonists of gonadotropin releasing hormone
08/19/1999	WO1999041248A1 Condensed heterocyclic system derivatives, preparation, pharmaceutical compositions containing them
08/19/1999	WO1999041246A1 Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
08/19/1999	WO1999041241A1 Heterocyclic topoisomerase poisons
08/19/1999	WO1999041235A1 Farnesyl transferase inhibitors
08/19/1999	WO1999041232A1 Cytostatic agents
08/19/1999	WO1999041230A1 Processes and intermediates useful to make antifolates
08/19/1999	WO1999041224A1 Biaryl-acetic acid derivatives and their use as cox-2 inhibitors
08/19/1999	WO1999040944A2 Hydroxylation activated drug release
08/19/1999	WO1999040925A2 Hapten-modified tumor cell membranes and their use
08/19/1999	WO1999040881A2 Specific antibodies against mammary tumor-associated mucin, method for production and use
08/19/1999	WO1999040837A2 Compositions for detecting and surgically removing lymphoid tissue involved in tumor progression
08/19/1999	WO1999032098A3 Combination of a ramba and a tocopherol
08/19/1999	WO1999030741A3 Agent for gene therapy of tumor, neurodegenerative, cardiovascular and autoimmune diseases
08/19/1999	WO1999030670A3 Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
08/19/1999	WO1999023108A9 Inducible phosphofructokinase and the warburg effect
08/19/1999	WO1999021845A3 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
08/19/1999	WO1999012945A3 Hydrophobic glycosylamine derivatives, compositions, and methods for use
08/19/1999	WO1999012570A3 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
08/19/1999	DE19859526A1 Pharmaceutical composition, especially for gene transfer and therapy
08/19/1999	DE19806438A1 New pyrimidinyloxy-propionic acid derivatives useful as endothelin receptor antagonists in treatment of e.g. cardiac insufficiency, restenosis, hypertension, kidney failure, asthma and prostate cancer
08/19/1999	DE19802377A1 Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs Use of inhibitors for the treatment of RTK function-related disorders, particularly cancer
08/19/1999	CA2321218A1 Condensed heterocyclic system derivatives, preparation, pharmaceutical compositions containing them
08/19/1999	CA2321135A1 Modified adenovirus containing a fiber replacement protein
08/19/1999	CA2321105A1 Human short-chain tnf-receptor family protein
08/19/1999	CA2320969A1 Hapten-modified tumor cell membranes, and methods of making and using hapten-modified tumor cell membranes
08/19/1999	CA2320960A1 Optimization of immunomodulatory properties of genetic vaccines
08/19/1999	CA2320626A1 Genetic vaccine vector engineering
08/19/1999	CA2320515A1 Therapeutic uses of keratinocyte growth factor-2
08/19/1999	CA2320431A1 Targeting of genetic vaccine vectors
08/19/1999	CA2320427A1 Human receptor proteins
08/19/1999	CA2320424A1 Human transport-associated molecules
08/19/1999	CA2320381A1 Cytostatic agents
08/19/1999	CA2319782A1 Retinoblastoma protein complexes and retinoblastoma interacting proteins
08/19/1999	CA2319688A1 Specific antibodies against mammary tumor-associated mucin, method for production and use
08/19/1999	CA2319424A1 Processes and intermediates useful to make antifolates
08/19/1999	CA2319173A1 Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
08/19/1999	CA2318966A1 Biaryl-acetic acid derivatives and their use as cox-2 inhibitors
08/19/1999	CA2318957A1 Antagonists of gonadotropin releasing hormone
08/19/1999	CA2318347A1 Heterocyclic topoisomerase poisons
08/19/1999	CA2317451A1 Antagonists of gonadotropin releasing hormone
08/19/1999	CA2312991A1 Prostate-associated serine protease
08/18/1999	EP0935963A2 The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders
08/18/1999	EP0935663A2 Multi-functional chimeric hematopoietic receptor agonists
08/18/1999	EP0935654A1 Fibroblast growth factor homologous factor-3 (fhf-3) and methods of use
08/18/1999	EP0935653A1 Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation
08/18/1999	EP0935651A2 THERAPY FOR $g(a)-GALACTOSIDASE A DEFICIENCY
08/18/1999	EP0935610A1 Novel human interferon-inducible protein
08/18/1999	EP0935605A1 Nucleic acid molecule encoding a bifunctional protein, the protein so encoded and uses thereof
08/18/1999	EP0935471A1 Mononuclear phagocytes in therapeutic drug delivery
08/18/1999	EP0935468A1 Use of cytokines and cytotoxic substances in a new method to treat tumors

1 ... 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 ... 2211